Pathogenesis and management of ANCA-associated vasculitis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) represent a group of three heterogeneous syndromes: granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome). They share a primary necrotizing small vessel vasculitis with propensity to involve the kidneys and the respiratory tract. The majority of patients with these syndromes have ANCA detectable in the serum at the time of diagnosis. Two types of ANCA are of clinical significance: C-ANCA reacting with the neutrophil enzyme proteinase 3 (PR3-ANCA) occur in over 80 % of patients with GPA and P-ANCA reacting with myeloperoxidase (MPO-ANCA) occur in less than 10 % of patients with GPA but in the majority of patients with MPA. MPO-ANCA is also the predominant type of ANCA encountered in patients with EGPA, where PR3-ANCA is the exception. The pathogenesis is not fully understood, but there is mounting evidence for a genetic predisposition, environmental triggers including infections, and ANCA all playing significant roles in the development of the syndromes. The outcome of untreated AAV with renal involvement is usually fatal. Treatment with the combination of glucocorticosteroids and cyclophosphamide (CYC) has turned these syndromes into manageable chronically relapsing disorders. Not all patients respond satisfactorily to CYC, and even for those who do, the subsequent relapse rate is high. Up to half of the patients who achieve remission relapse within the first 3-5 years. The need for retreatment exposes patients to significant long-term toxicities of glucocorticoids and less toxic alternatives have been sought. Rituximab has recently emerged as an alternative for CYC and currently represents the only FDA-approved treatment for remission induction in patients with severe AAV. This chapter reviews recent advances in the pathogenesis and treatment of AAV.

Original languageEnglish (US)
Title of host publicationCore Concepts in Parenchymal Kidney Disease
PublisherSpringer New York
Pages137-151
Number of pages15
ISBN (Print)9781461481669, 1461481651, 9781461481652
DOIs
StatePublished - Jul 1 2013

Fingerprint

Antineutrophil Cytoplasmic Antibodies
Vasculitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Granulomatosis with Polyangiitis
Microscopic Polyangiitis
Cyclophosphamide
Myeloblastin
Churg-Strauss Syndrome
Kidney
Remission Induction
Recurrence
Retreatment
Poisons
Genetic Predisposition to Disease
Respiratory System
Glucocorticoids
Peroxidase
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Specks, U. (2013). Pathogenesis and management of ANCA-associated vasculitis. In Core Concepts in Parenchymal Kidney Disease (pp. 137-151). Springer New York. https://doi.org/10.1007/978-1-4614-8166-9_10

Pathogenesis and management of ANCA-associated vasculitis. / Specks, Ulrich.

Core Concepts in Parenchymal Kidney Disease. Springer New York, 2013. p. 137-151.

Research output: Chapter in Book/Report/Conference proceedingChapter

Specks, U 2013, Pathogenesis and management of ANCA-associated vasculitis. in Core Concepts in Parenchymal Kidney Disease. Springer New York, pp. 137-151. https://doi.org/10.1007/978-1-4614-8166-9_10
Specks U. Pathogenesis and management of ANCA-associated vasculitis. In Core Concepts in Parenchymal Kidney Disease. Springer New York. 2013. p. 137-151 https://doi.org/10.1007/978-1-4614-8166-9_10
Specks, Ulrich. / Pathogenesis and management of ANCA-associated vasculitis. Core Concepts in Parenchymal Kidney Disease. Springer New York, 2013. pp. 137-151
@inbook{ad00c3385952406382b04aa636d043e8,
title = "Pathogenesis and management of ANCA-associated vasculitis",
abstract = "The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) represent a group of three heterogeneous syndromes: granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome). They share a primary necrotizing small vessel vasculitis with propensity to involve the kidneys and the respiratory tract. The majority of patients with these syndromes have ANCA detectable in the serum at the time of diagnosis. Two types of ANCA are of clinical significance: C-ANCA reacting with the neutrophil enzyme proteinase 3 (PR3-ANCA) occur in over 80 {\%} of patients with GPA and P-ANCA reacting with myeloperoxidase (MPO-ANCA) occur in less than 10 {\%} of patients with GPA but in the majority of patients with MPA. MPO-ANCA is also the predominant type of ANCA encountered in patients with EGPA, where PR3-ANCA is the exception. The pathogenesis is not fully understood, but there is mounting evidence for a genetic predisposition, environmental triggers including infections, and ANCA all playing significant roles in the development of the syndromes. The outcome of untreated AAV with renal involvement is usually fatal. Treatment with the combination of glucocorticosteroids and cyclophosphamide (CYC) has turned these syndromes into manageable chronically relapsing disorders. Not all patients respond satisfactorily to CYC, and even for those who do, the subsequent relapse rate is high. Up to half of the patients who achieve remission relapse within the first 3-5 years. The need for retreatment exposes patients to significant long-term toxicities of glucocorticoids and less toxic alternatives have been sought. Rituximab has recently emerged as an alternative for CYC and currently represents the only FDA-approved treatment for remission induction in patients with severe AAV. This chapter reviews recent advances in the pathogenesis and treatment of AAV.",
author = "Ulrich Specks",
year = "2013",
month = "7",
day = "1",
doi = "10.1007/978-1-4614-8166-9_10",
language = "English (US)",
isbn = "9781461481669",
pages = "137--151",
booktitle = "Core Concepts in Parenchymal Kidney Disease",
publisher = "Springer New York",

}

TY - CHAP

T1 - Pathogenesis and management of ANCA-associated vasculitis

AU - Specks, Ulrich

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) represent a group of three heterogeneous syndromes: granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome). They share a primary necrotizing small vessel vasculitis with propensity to involve the kidneys and the respiratory tract. The majority of patients with these syndromes have ANCA detectable in the serum at the time of diagnosis. Two types of ANCA are of clinical significance: C-ANCA reacting with the neutrophil enzyme proteinase 3 (PR3-ANCA) occur in over 80 % of patients with GPA and P-ANCA reacting with myeloperoxidase (MPO-ANCA) occur in less than 10 % of patients with GPA but in the majority of patients with MPA. MPO-ANCA is also the predominant type of ANCA encountered in patients with EGPA, where PR3-ANCA is the exception. The pathogenesis is not fully understood, but there is mounting evidence for a genetic predisposition, environmental triggers including infections, and ANCA all playing significant roles in the development of the syndromes. The outcome of untreated AAV with renal involvement is usually fatal. Treatment with the combination of glucocorticosteroids and cyclophosphamide (CYC) has turned these syndromes into manageable chronically relapsing disorders. Not all patients respond satisfactorily to CYC, and even for those who do, the subsequent relapse rate is high. Up to half of the patients who achieve remission relapse within the first 3-5 years. The need for retreatment exposes patients to significant long-term toxicities of glucocorticoids and less toxic alternatives have been sought. Rituximab has recently emerged as an alternative for CYC and currently represents the only FDA-approved treatment for remission induction in patients with severe AAV. This chapter reviews recent advances in the pathogenesis and treatment of AAV.

AB - The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) represent a group of three heterogeneous syndromes: granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome). They share a primary necrotizing small vessel vasculitis with propensity to involve the kidneys and the respiratory tract. The majority of patients with these syndromes have ANCA detectable in the serum at the time of diagnosis. Two types of ANCA are of clinical significance: C-ANCA reacting with the neutrophil enzyme proteinase 3 (PR3-ANCA) occur in over 80 % of patients with GPA and P-ANCA reacting with myeloperoxidase (MPO-ANCA) occur in less than 10 % of patients with GPA but in the majority of patients with MPA. MPO-ANCA is also the predominant type of ANCA encountered in patients with EGPA, where PR3-ANCA is the exception. The pathogenesis is not fully understood, but there is mounting evidence for a genetic predisposition, environmental triggers including infections, and ANCA all playing significant roles in the development of the syndromes. The outcome of untreated AAV with renal involvement is usually fatal. Treatment with the combination of glucocorticosteroids and cyclophosphamide (CYC) has turned these syndromes into manageable chronically relapsing disorders. Not all patients respond satisfactorily to CYC, and even for those who do, the subsequent relapse rate is high. Up to half of the patients who achieve remission relapse within the first 3-5 years. The need for retreatment exposes patients to significant long-term toxicities of glucocorticoids and less toxic alternatives have been sought. Rituximab has recently emerged as an alternative for CYC and currently represents the only FDA-approved treatment for remission induction in patients with severe AAV. This chapter reviews recent advances in the pathogenesis and treatment of AAV.

UR - http://www.scopus.com/inward/record.url?scp=84929536074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929536074&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-8166-9_10

DO - 10.1007/978-1-4614-8166-9_10

M3 - Chapter

AN - SCOPUS:84929536074

SN - 9781461481669

SN - 1461481651

SN - 9781461481652

SP - 137

EP - 151

BT - Core Concepts in Parenchymal Kidney Disease

PB - Springer New York

ER -